Company: AGIO
Filing Date: 2025-07-31
Form Type: 10-Q
Source: 0001439222-25-000089
Chunk: 116

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-07-31
Form: 10-Q
Item: Part I, Item 1
Chunk 116
---
Accounts receivable, net(877)(952)Inventory(3,232)(4,861)Prepaid expenses and other current and non-current assets(3,746)486 Accounts payable1,084 268 Accrued expenses and other current liabilities(11,572)(6,425)Income taxes payable(871)— Operating lease liabilities(8,228)(7,376)Other non-current liabilities(779)— Net cash used in operating activities(188,613)(172,456)Investing activitiesPurchases of marketable securities(305,700)(348,604)Proceeds from maturities and sales of marketable securities508,894 510,669 Payments associated with license agreement(10,000)— Purchases of property and equipment(1,641)(299)Proceeds from sale of equipment— 40 Net cash provided by investing activities191,553 161,806 Financing activitiesNet proceeds from stock option exercises and employee stock purchase plan1,684 6,963 Net cash provided by financing activities1,684 6,963 Net change in cash and cash equivalents4,624 (3,687)Cash and cash equivalents at beginning of the period76,247 88,205 Cash and cash equivalents at end of the period$80,871 $84,518 Supplemental disclosure of non-cash investing and financing transactionsAdditions to property and equipment in accounts payable$122 $42 Net cash taxes paid (returned)$1,503 $(603)

See accompanying Notes to Condensed Consolidated Financial Statements.

5

AGIOS PHARMACEUTICALS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1. Overview and Basis of Presentation

References to AgiosThroughout this Quarterly Report on Form 10-Q, "Agios," "the company," “we,” “us,” and “our,” and similar expressions, except where the context requires otherwise, refer to Agios Pharmaceuticals, Inc. and its consolidated subsidiaries, and “our Board of Directors” refers to the board of directors of Agios Pharmaceuticals, Inc.OverviewWe are a biopharmaceutical company committed to transforming patients’ lives through leadership in the field of cellular metabolism, with the goal of creating differentiated medicines for rare diseases, with a focus on classical hematology. With a history of focused study on cellular metabolism, we have a deep and mature understanding of this biology, which is involved in the healthy functioning